Enhancing H2 evolution performance of an immobilised cobalt catalyst by rational ligand design.

The catalyst [CoIIIBr((DO)(DOH)(4-BnPO3H2)(2-CH2py)pn)]Br, CoP3 , has been synthesised to improve the stability and activity of cobalt catalysts immobilised on metal oxide surfaces. The CoP3 catalyst contains an equatorial diimine-dioxime ligand, (DOH)2pn = N2,N2'-propanediyl-bis(2,3-butanedione-2-imine-3-oxime), with a benzylphosphonic acid (4-BnPO3H2) group and a methylpyridine (2-CH2py) ligand covalently linked to the bridgehead of the pseudo-macrocyclic diimine-dioxime ligand. The phosphonic acid functionality provides a robust anchoring group for immobilisation on metal oxides, whereas the pyridine is coordinated to the Co ion to enhance the catalytic activity of the catalyst. Electrochemical investigations in solution confirm that CoP3 shows electrocatalytic activity for the reduction of aqueous protons between pH 3 and 7. The metal oxide anchor provides the catalyst with a high affinity for mesostructured Sn-doped In2O3 electrodes (mesoITO; loading of approximately 22 nmol cm-2) and the electrostability of the attached CoP3 was confirmed by cyclic voltammetry. Finally, immobilisation of the catalyst on ruthenium-dye sensitised TiO2 nanoparticles in aqueous solutions in the presence of a hole scavenger establishes the activity of the catalyst in this photocatalytic scheme. The advantages of the elaborate catalyst design in CoP3 in terms of stability and catalytic activity are shown by direct comparison with previously reported phosphonated Co catalysts. We therefore demonstrate that rational ligand design is a viable route for improving the performance of immobilised molecular catalysts.Support by the Christian Doppler Research Association (Austrian Federal Ministry of Science, Research and Economy and National Foundation for Research, Technology and Development), the OMV Group and the EPSRC (EP/H00338X/2) is gratefully acknowledged.This is the final published version. It first appeared at http://pubs.rsc.org/en/Content/ArticleLanding/2015/SC/c4sc03946g#!divAbstract

Bis(α-diimine)iron Complexes: Electronic Structure Determination by Spectroscopy and Broken Symmetry Density Functional Theoretical Calculations

The electronic structure of a family comprising tetrahedral (α-diimine)iron dichloride, and tetrahedral bis(α-diimine)iron compounds has been investigated by Mössbauer spectroscopy, magnetic susceptibility measurements, and X-ray crystallography. In addition, broken-symmetry density functional theoretical (B3LYP) calculations have been performed. A detailed understanding of the electronic structure of these complexes has been obtained. A paramagnetic (S_t = 2), tetrahedral complex [Fe^(II)(^4L)_2], where (^4L)^(1−) represents the diamagnetic monoanion N-tert-butylquinolinylamide, has been synthesized and characterized to serve as a benchmark for a Werner-type complex containing a tetrahedral Fe^(II)N_4 geometry and a single high-spin ferrous ion. In contrast to the most commonly used description of the electronic structure of bis(α-diimine)iron(0) complexes as low-valent iron(0) species with two neutral α-diimine ligands, it is established here that they are, in fact, complexes containing two (α-diiminato)^(1−•) π radical monoanions and a high-spin ferrous ion (in tetrahedral N_4 geometry) (S_(Fe) = 2). Intramolecular antiferromagnetic coupling between the π radical ligands (S_(rad) = 1/2) and the ferrous ion (S_(Fe) = 2) yields the observed S_t = 1 ground state. The study confirms that α-diimines are redox noninnocent ligands with an energetically low-lying antibonding π^* lowest unoccupied molecular orbital which can accept one or two electrons from a transition metal ion. The (α-diimine)FeCl_2 complexes (St = 2) are shown to contain a neutral α-diimine ligand, a high spin ferrous ion, and two chloride ligands

Distance dependent charge separation and recombination in semiconductor/molecular catalyst systems for water splitting

The photoinduced reduction of three Co electrocatalysts immobilised on TiO(2) is 10(4) times faster than the reverse charge recombination. Both processes show an exponential dependence on the distance between the semiconductor and the catalytic core

The Changing Landscape for Stroke\ua0Prevention in AF: Findings From the GLORIA-AF Registry Phase 2

Background GLORIA-AF (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation) is a prospective, global registry program describing antithrombotic treatment patterns in patients with newly diagnosed nonvalvular atrial fibrillation at risk of stroke. Phase 2 began when dabigatran, the first non\u2013vitamin K antagonist oral anticoagulant (NOAC), became available. Objectives This study sought to describe phase 2 baseline data and compare these with the pre-NOAC era collected during phase 1. Methods During phase 2, 15,641 consenting patients were enrolled (November 2011 to December 2014); 15,092 were eligible. This pre-specified cross-sectional analysis describes eligible patients\u2019 baseline characteristics. Atrial fibrillation disease characteristics, medical outcomes, and concomitant diseases and medications were collected. Data were analyzed using descriptive statistics. Results Of the total patients, 45.5% were female; median age was 71 (interquartile range: 64, 78) years. Patients were from Europe (47.1%), North America (22.5%), Asia (20.3%), Latin America (6.0%), and the Middle East/Africa (4.0%). Most had high stroke risk (CHA2DS2-VASc [Congestive heart failure, Hypertension, Age  6575 years, Diabetes mellitus, previous Stroke, Vascular disease, Age 65 to 74 years, Sex category] score  652; 86.1%); 13.9% had moderate risk (CHA2DS2-VASc = 1). Overall, 79.9% received oral anticoagulants, of whom 47.6% received NOAC and 32.3% vitamin K antagonists (VKA); 12.1% received antiplatelet agents; 7.8% received no antithrombotic treatment. For comparison, the proportion of phase 1 patients (of N = 1,063 all eligible) prescribed VKA was 32.8%, acetylsalicylic acid 41.7%, and no therapy 20.2%. In Europe in phase 2, treatment with NOAC was more common than VKA (52.3% and 37.8%, respectively); 6.0% of patients received antiplatelet treatment; and 3.8% received no antithrombotic treatment. In North America, 52.1%, 26.2%, and 14.0% of patients received NOAC, VKA, and antiplatelet drugs, respectively; 7.5% received no antithrombotic treatment. NOAC use was less common in Asia (27.7%), where 27.5% of patients received VKA, 25.0% antiplatelet drugs, and 19.8% no antithrombotic treatment. Conclusions The baseline data from GLORIA-AF phase 2 demonstrate that in newly diagnosed nonvalvular atrial fibrillation patients, NOAC have been highly adopted into practice, becoming more frequently prescribed than VKA in Europe and North America. Worldwide, however, a large proportion of patients remain undertreated, particularly in Asia and North America. (Global Registry on Long-Term Oral Antithrombotic Treatment in Patients With Atrial Fibrillation [GLORIA-AF]; NCT01468701

Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry

International audienceIn this article, the name of the GLORIA-AF investigator Anastasios Kollias was given incorrectly as Athanasios Kollias in the Acknowledgements. The original article has been corrected

Patterns of oral anticoagulant use and outcomes in Asian patients with atrial fibrillation: a post-hoc analysis from the GLORIA-AF Registry

Background: Previous studies suggested potential ethnic differences in the management and outcomes of atrial fibrillation (AF). We aim to analyse oral anticoagulant (OAC) prescription, discontinuation, and risk of adverse outcomes in Asian patients with AF, using data from a global prospective cohort study. Methods: From the GLORIA-AF Registry Phase II-III (November 2011-December 2014 for Phase II, and January 2014-December 2016 for Phase III), we analysed patients according to their self-reported ethnicity (Asian vs. non-Asian), as well as according to Asian subgroups (Chinese, Japanese, Korean and other Asian). Logistic regression was used to analyse OAC prescription, while the risk of OAC discontinuation and adverse outcomes were analysed through Cox-regression model. Our primary outcome was the composite of all-cause death and major adverse cardiovascular events (MACE). The original studies were registered with ClinicalTrials.gov, NCT01468701, NCT01671007, and NCT01937377. Findings: 34,421 patients were included (70.0 ± 10.5 years, 45.1% females, 6900 (20.0%) Asian: 3829 (55.5%) Chinese, 814 (11.8%) Japanese, 1964 (28.5%) Korean and 293 (4.2%) other Asian). Most of the Asian patients were recruited in Asia (n = 6701, 97.1%), while non-Asian patients were mainly recruited in Europe (n = 15,449, 56.1%) and North America (n = 8378, 30.4%). Compared to non-Asian individuals, prescription of OAC and non-vitamin K antagonist oral anticoagulant (NOAC) was lower in Asian patients (Odds Ratio [OR] and 95% Confidence Intervals (CI): 0.23 [0.22-0.25] and 0.66 [0.61-0.71], respectively), but higher in the Japanese subgroup. Asian ethnicity was also associated with higher risk of OAC discontinuation (Hazard Ratio [HR] and [95% CI]: 1.79 [1.67-1.92]), and lower risk of the primary composite outcome (HR [95% CI]: 0.86 [0.76-0.96]). Among the exploratory secondary outcomes, Asian ethnicity was associated with higher risks of thromboembolism and intracranial haemorrhage, and lower risk of major bleeding. Interpretation: Our results showed that Asian patients with AF showed suboptimal thromboembolic risk management and a specific risk profile of adverse outcomes; these differences may also reflect differences in country-specific factors. Ensuring integrated and appropriate treatment of these patients is crucial to improve their prognosis. Funding: The GLORIA-AF Registry was funded by Boehringer Ingelheim GmbH